Table 2 Clinical and genetic features across diagnostic groups

N

59

31

29

49

97

51

Onset < 65 years, %

40 (67.8)^a–e

13 (41.9)

11 (37.9)

14 (28.6)^d

47 (48.4)

19 (37.3)

MMSE score, /30

24.8 (3.9)^d

25.4 (5.1)^d

24.3 (5.5)

23.1 (5.3)

21.9 (6.2)^e

25.6 (3.7)

Brief Mental Deterioration Battery

0.1 (1.5)

0.5 (1.1)

0.3 (1.3)

− 0.2 (1.2)

− 0.5 (1.4)

0.1 (1.6)

CDR score ≥ 1, %^°

40 (81.6)^e,f

17 (54.8)^d

19 (67.9)

34 (69.4)

66 (77.6)^g

29 (56.8)

CDR score ≥ 2, %^°

18 (41.9)

6 (19.4)

5 (17.9)

14 (28.6)

33 (38.8)

12 (23.5)

ADL/IADL impairment, %

51 (86.4)^f,h,i

18 (58.1)^j

24 (82.7)^g

34 (69.4)

74 (76.2)^e

28 (54.9)

CSF A+, %

2 (3.4)^c,k,l

4 (12.9)^b,g,l,m

14 (48.3)^i,l

18 (36.7)^i,l

97 (100)ⁱ

0 (0.0)

CSF T+, %

2 (3.4)^k,l,m

3 (9.7)^b,l

12 (41.4)^e,l,m

7 (14.3)^l

94 (96.9)ⁱ

2 (3.9)

CSF N+, %

6 (10.2)^l

1 (3.2)^l,n

7 (24.1)^l

7 (14.3)^l

73 (75.2)ⁱ

6 (11.7)

Positive α-syn RT-QuIC test, %

0 (0.0)^c,l

0 (0.0)^c,d

1 (3.4)^c

47 (95.9)^i,l

15 (15.5)ⁱ

1 (1.9)

APOE ε4, positive/tested, %

12/51 (23.5)^g

6/31 (19.3)

6/27 (22.2)

13/49 (26.5)^e

35/94 (37.2)ⁱ

5/50 (10.0)

Monogenic disease, positive/tested, %

18/37 (48.6)*

0/8 (0.0)

0/12 (0.0)

–

–

–